Teva 4Q Revenues: $4.9 billion (-6%) 4Q Earnings: $498 million (-28%) FY Revenues: $19.7 billion (-3%) FY Earnings: $1.6 billion (-48%) Comments: Specialty Medicines revenue was $2.1 billion in the quarter, down 6%, primarily due to lower sales of Copaxone and Azilect, which were partially offset by higher revenues of respiratory products. Specialty Medicines accounted for 44% of total revenues in the quarter. Generic Medicines revenue was $2.3 billion in the quarter, down 9%. R&a...